SCHEMBL4477265

SCHEMBL4477265

Cc1cc(C)c2c(C#N)c(/C=C/C(=O)Nc3ccc(Cl)cc3)n([C@H]3CCCc4ccccc43)c2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
RECQL P46063 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
EGFR P00533 1/20 0.34
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MAPT P10636 3/20 0.34
KDM4E B2RXH2 2/20 0.34
RGS12 O14924 1/20 0.34
G6PD P11413 1/20 0.34
CREBBP Q92793 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
HTR2C P28335 1/20 0.34
DRD3 P35462 1/20 0.34
MCHR1 Q99705 4/20 0.33
PTGS2 P35354 2/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477274 1.00 LMNA (0.40) LMNAKMT2AMEN1RECQLNPSR1
SCHEMBL4477525 0.94 ATM (0.36) LMNAKMT2AEGFRMMP1MMP2
SCHEMBL4477532 0.94 ATM (0.36) LMNAKMT2AEGFRMMP1MMP2
SCHEMBL4475609 0.94 KMT2A (0.37) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL4475604 0.94 KMT2A (0.37) LMNAKMT2AMEN1MAPTKDM4E
SCHEMBL4484201 0.93 POLB (0.37) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL4492162 0.93 LMNA (0.37) LMNAKMT2AKDM4EALDH1A1RAB9A
SCHEMBL4484206 0.93 POLB (0.37) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL4492169 0.93 LMNA (0.37) LMNAKMT2AKDM4EALDH1A1RAB9A
SCHEMBL4470407 0.93 EGFR (0.37) LMNAKMT2AMEN1EGFRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582651-B2 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-01 US disclosed
US-20060167038-A1 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-27 US disclosed
EP-1535922-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167038-A1 Pyrrolopyridine derivative and use thereof OPRD1, TRPV1, OPRM1 LMNA 4879/4885KMT2A 3881/4885MEN1 4657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.